Ultrasound-driven plant lipid vesicles amplify oncolytic virotherapy in colorectal cancer.

Authors

Baoyi Li, Xiaoyan Li, Yuntian Deng, Yuting Luo, Yu Huang, Dan She, Huiling Li, Shuhui Ji, Ga Liu, Yajun Wang, Menghang Zu, Subhas C Kundu, Peijing Zhang, Peng Lv, Xiaoxiao Shi, Bo Xiao

Published in

Journal of controlled release : official journal of the Controlled Release Society. Pages 115368. Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Colorectal cancer (CRC) remains a highly aggressive malignancy, and its treatment with oncolytic virotherapy is hindered by multiple delivery barriers and delayed therapeutic kinetics. To address these challenges, we developed a plant lipid-based vesicular system (P-M@Ce6-OVs) co-encapsulating oncolytic viruses (OVs) and sonosensitizer chlorin e6 (Ce6), enabling ultrasound (US)-guided, spatiotemporally controlled delivery to deep colorectal tumors. Under US exposure, the system enhanced mucus infiltration, tumor penetration, and lysosomal escape, while activating sonodynamic therapy to rapidly induce tumor ablation and compensate delayed viral oncolysis. In CRC mouse models, rectal administration of P-M@Ce6-OVs with US exposure achieved a 10.3-fold reduction in tumor burden compared with the control (without treatment), markedly outperforming monotherapies. Importantly, combination with αPD-L1 not only suppressed primary CRC and re-challenged tumors mimicking metastatic relapse, but also induced durable systemic immune protection. This triple combination further potentiated systemic and mucosal antitumor immunity, restoring cytotoxic T-cell function and reinforcing humoral and gut-localized immune responses. Notably, this treatment reshaped gut microbiota by enriching nucleoside-metabolizing bacteria (e.g., Lactobacillus taiwanensis) and altering microbial metabolic profiles, including the pathways related to pyrimidine catabolism and arachidonic acid oxidation. These microbiota and metabolic changes were associated with immune remodeling and tumor suppression. Collectively, this platform integrated US-enabled delivery, sonodynamic activation, and microbiome remodeling to synergistically suppress CRC and re-challenged tumor progression, amplifying virotherapy and antitumor immunity.

PMID:
42753826
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.